Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH

NACompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Non Alcoholic Fatty Liver Disease
Interventions
OTHER

Evaluation of the staging of fibrosis liver

The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies

OTHER

Determine the expression level of semaphorin

The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,

OTHER

Determination of the composition of immunity cells

"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"

Trial Locations (1)

06003

Service d'Hépato-Gastroentérologie - Hôpital de l'Archet, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT02820285 - Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH | Biotech Hunter | Biotech Hunter